ARA-290 Dosage, Reconstitution & Mixing Trends

Explore ara-290 calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized ara-290 calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What ARA-290 Is

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin, most often sourced for neuropathic-pain and tissue-repair research. It was engineered to keep EPO's tissue-protective signal without raising red-blood-cell counts. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]

Cibinetide binds the innate-repair receptor (IRR), a heteromeric receptor formed by the EPO receptor and the β-common (CD131) receptor. IRR activation is anti-inflammatory and tissue-protective but, critically, does not engage the homodimeric EPO-receptor complex that drives erythropoiesis — so the molecule does not raise hematocrit or red-blood-cell mass at therapeutic doses.[2]

A Phase 2 trial in sarcoidosis-associated small-fiber neuropathy (Heij et al., Mol Med 2017) reported improvements in neuropathic pain and small-fiber metrics versus placebo after 28 days.[3] Additional Phase 2 work in chronic neuropathic pain, ophthalmologic dry-eye disease, and diabetic macular edema has been reported by Araim, with mixed results across endpoints.

Not FDA-approved. Phase 2 trials by Araim Pharmaceuticals in neuropathic pain, sarcoidosis SFN, and dry-eye indications; no Phase 3 program initiated. Research-grade material only.

ARA-290 Research Sources

ARA-290 Dosing Context

ARA-290 has a reported half-life of ~2 min (plasma). The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. Disappears from the blood within minutes, so there is no buildup at all. The benefit comes from triggering a longer-lasting tissue response, not from a steady blood level. Pharmacokinetic source: Brines et al. Mol Med 2014 (ARA-290 / cibinetide clinical PK). It is catalogued under Recovery Peptides on WPA.

ARA-290 Community Calculator Data

499 ARA-290 reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

ARA-290 Research Background and Calculator Data

ARA-290 — also known as cibinetide — is an 11-amino-acid peptide derived from the helix-B region of erythropoietin, designed by the Anthony Cerami group at Araim Pharmaceuticals (founded as the spinout from the original Kenneth Brines / Michael Brines tissue-protective EPO work) to retain EPO's tissue-protective signaling while removing the red-cell-stimulating activity that limits EPO's clinical use. The molecular logic is unusually clean: EPO's erythropoietic effect requires homodimeric EPOR-EPOR receptor binding, while its tissue-protective effect signals through a separate heteromeric "innate repair receptor" (IRR) composed of EPOR and the beta-common receptor (CD131); cibinetide was engineered to bind the IRR without activating the EPOR homodimer. The downstream preclinical literature established cibinetide as broadly tissue-protective in models of neuropathy, ischemic injury, retinal damage, and autoimmune inflammation — and crucially, animal studies confirmed the absence of any erythropoietic effect at doses that produced clear tissue-protective signal. The most clinically substantive evidence base is the Brines et al. and Schmidt et al. clinical work in small-fiber neuropathy in sarcoidosis, where Phase II trials of cibinetide at 4mg subcutaneously once daily produced measurable improvements in corneal nerve fiber density and patient-reported neuropathic pain measures over 4-week and 28-day treatment windows — published evidence that puts cibinetide further along the human clinical record than most non-FDA-approved peptides on this site, even though the program has not yet produced a labeled indication.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.